Pancreatic Cell News 8.48 December 5, 2017 | |
| |
TOP STORYInactivation of DNA Repair Triggers Neoantigen Generation and Impairs Tumor Growth Scientists genetically inactivated MutL homologue 1 (MLH1) in colorectal, breast and pancreatic mouse cancer cells. The growth of DNA mismatch repair-deficient cells was comparable to their proficient counterparts in vitro and on transplantation in immunocompromised mice. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISNeuronal Signals Regulate Obesity Induced β-Cell Proliferation by FoxM1 Dependent Mechanism Researchers identified forkhead box M1 (FoxM1) activation in islets from neuronal relay-stimulated mice. Blockade of this relay, including vagotomy, inhibited obesity-induced activation of the β-cell FoxM1 pathway and suppressed β-cell expansion. [Nat Commun] Full Article Scientists showed that islet cells expressing insulin, glucagon, or somatostatin share a lack of methylation at the promoters of the insulin and glucagon genes. [Proc Natl Acad Sci USA] Full Article Estrogen Attenuates AGTR1 Expression to Reduce Pancreatic β-Cell Death from High Glucose The authors examined whether estrogen protects against pancreatic β-cell death caused by glucotoxicity via a decrease in the pancreatic β-cell renin-angiotensin system pathway. [Sci Rep] Full Article A Subclass of Serum Anti-ZnT8 Antibodies Directed to the Surface of Live Pancreatic Beta-Cells ZnT8 antibody (ZnT8A) binding was detected on live rat insulinoma INS-1E cells, and the binding specificity was validated by a CRISPR/Cas9 mediated ZnT8-knockout. Applying established ZnT8A assays to purified serum antibodies from patients with type-1 diabetes, researchers detected human ZnT8A bound to live INS-1E cells, while a ZnT8-knockout specifically reduced the surface binding. [J Biol Chem] Abstract The authors found that transition pore inhibitor 3,5-seco-4-nor-cholestan-5-one oxime-3-ol (TRO40303) protects mitochondria and prevents necrotic cell death pathway activation in murine and human pancreatic acinar cells, ameliorates the severity of experimental alcoholic acute pancreatitis (AP), and is a candidate drug for human AP. [Pancreas] Abstract PANCREATIC CANCERTo characterize pancreatic cancer cells from different sources, which are used as model systems to study the metastatic behavior in pancreatic ductal adenocarcinoma (PDAC), researchers compared the N-glycan imprint of four PDAC cells which were previously shown to differ in their galectin-4 expression and metastatic potential in vivo. [Sci Rep] Full Article The authors report a novel role for the beta-galactoside alpha-2,6-sialyltransferase I (ST6Gal-I) sialyltransferase in gemcitabine resistance. Utilizing MiaPaCa-2 and BxPC-3 pancreatic ductal adenocarcinoma cells, they found that knockdown of ST6Gal-I expression, as well as removal of surface α2-6 sialic acids by neuraminidase, enhances gemcitabine-mediated cell death assessed via colonogenic assays and cleaved caspase 3 expression. [J Biol Chem] Abstract | Full Article Investigators examined the effect of epidermal growth factor (EGF)-conjugated liposomes containing curcumin on three different EGFR-expressed human pancreatic cancer cell lines, BxPC-3, Panc-1 and Mia Paca-2. [J Drug Target] Abstract The authors developed and applied an in-vitro 3D tumor-extracellular matrix (ECM) model to define how ECM composition and biophysical properties modulate pancreatic cancer epithelial to mesenchymal transition (EMT). [PLoS One] Full Article miR-135b-5p Promotes Migration, Invasion and EMT of Pancreatic Cancer Cells by Targeting NR3C2 Scientists elucidated the potential functional mechanism of miR-135b-5p in migration, invasion and epithelial-to-mesenchymal transition (EMT) of pancreatic cancer cells. By real-time PCR and analysis of GEO database, they determined the up-regulated expression of miR-135b-5p in pancreatic cancer tissues and cell lines. [Biomed Pharmacother] Abstract | Graphical Abstract | |
| |
REVIEWSResearchers highlight the important role the complex structure of stroma in pancreatic ductal adenocarcinoma plays in the intrinsic resistance to gemcitabine (GEM) and discuss whether antistroma therapy improves the efficacy of GEM. [Exp Mol Med] Full Article Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSFirst of Its Kind Pancreatic Cancer Trial to Begin in Scotland A ground-breaking new pancreatic cancer trial, which aims to match patients with more targeted and effective treatment for their tumors, is to begin in Scotland. Run by Precision-Panc, a research program and clinical trials project led by the University of Glasgow and majority-funded by Cancer Research UK, the trial will bring a precision medicine approach to pancreatic cancer treatment for the first time in the UK. [University of Glasgow] Press Release Sanofi’s Toujeo® Met Main Objective in Head-to-Head Study versus Insulin Degludec Sanofi’s Toujeo® met the primary study objective in the first large head-to-head clinical trial, called BRIGHT study, comparing Toujeo with insulin degludec. The BRIGHT study included adults with type 2 diabetes who had failed to control their HbA1c with oral antihyperglycemic drugs with or without a glucagon-like peptide-1 receptor agonist. [Sanofi S.A.] Press Release | |
| |
POLICY NEWSTrump Science Job Nominees Missing Advanced Science Degrees When it comes to filling jobs dealing with complex science, environment, and health issues, the Trump administration is nominating people with fewer science academic credentials than their Obama predecessors. And it’s moving slower as well. [STAT News] Editorial Biohackers Disregard FDA Warning on DIY Gene Therapy Despite a warning from the federal government about do-it-yourself (DIY) gene therapy, two companies say they’ll continue offering DNA-altering materials to the public. The companies, The Odin and Ascendance Biomedical, both recently posted videos online of people self-administering DNA molecules their labs had produced. [MIT Technology Review] Editorial Health Agency Reveals Scourge of Fake Drugs in Developing World One in ten medicines in developing countries is fake or substandard, data from the World Health Organization suggest. Malaria drugs and antibiotics are among the most commonly reported, the agency found. But the problem extends to a variety of medications, including those for cancer, heart disease and HIV, as well as contraceptives and painkillers. [Nature News] Editorial
| |
EVENTSNEW Boston Ithaca Islet Club Meeting 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Studentship – Pancreatic Cancer (CRUK Manchester Institute) NEW Postdoctoral Research Scientist – Type 2 Diabetes (Novo Nordisk) NEW Postdoctoral Fellowship (Memorial Sloan Kettering Cancer Center) Research Technologist – Pancreatic Cell Biology (STEMCELL Technologies Inc.) PhD Studentship – Pancreas Development and Stem Cells (Helmholtz Zentrum München) Postdoctoral Positions – Pancreatic Cancer (MD Anderson Cancer Center) Postdoctoral Position – Pathogenesis of Type 1 Diabetes (Helmholtz Zentrum München) Postdoctoral Fellowship Positions – Pancreatic Cancer (Translational Genomics Research Institute) Scientist – Diabetes and Obesity (Helmholtz Zentrum München) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|